Market Closed -
Nasdaq
04:30:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.87
USD
|
+0.54%
|
|
0.00%
|
-51.43%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
83.31
|
75.24
|
168.7
|
53.6
|
35.38
|
21.78
|
-
|
-
|
Enterprise Value (EV)
1 |
-36.26
|
-25.2
|
32.07
|
-24.03
|
35.38
|
-5.62
|
-45.62
|
21.78
|
P/E ratio
|
-1.52
x
|
-1.31
x
|
-2.22
x
|
-0.83
x
|
-0.44
x
|
-0.74
x
|
-0.49
x
|
-0.27
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
37.5
x
|
138
x
|
96.2
x
|
45.4
x
|
10.5
x
|
82.7
x
|
4.86
x
|
0.96
x
|
EV / Revenue
|
-16.3
x
|
-46.2
x
|
18.3
x
|
-20.4
x
|
10.5
x
|
-21.3
x
|
-10.2
x
|
0.96
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
472,643
x
|
349,878
x
|
-606,451
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
0%
|
0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
2,153
|
2,322
|
4,647
|
4,701
|
9,189
|
11,647
|
-
|
-
|
Reference price
2 |
38.70
|
32.40
|
36.30
|
11.40
|
3.850
|
1.870
|
1.870
|
1.870
|
Announcement Date
|
3/12/20
|
3/25/21
|
3/17/22
|
3/29/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2.224
|
0.545
|
1.754
|
1.18
|
3.371
|
0.2633
|
4.478
|
22.75
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-54.41
|
-60.47
|
-60.76
|
-67.42
|
-55.16
|
-29.21
|
-77.63
|
-78.85
|
Operating Margin
|
-2,446.45%
|
-11,094.68%
|
-3,464.37%
|
-5,713.47%
|
-1,636.34%
|
-11,092.55%
|
-1,733.56%
|
-346.58%
|
Earnings before Tax (EBT)
1 |
-51.37
|
-59.17
|
-60.56
|
-66.15
|
-57.27
|
-26.89
|
-75.26
|
-76.44
|
Net income
1 |
-51.37
|
-59.17
|
-60.56
|
-66.15
|
-57.28
|
-24.55
|
-43.23
|
-76.44
|
Net margin
|
-2,309.94%
|
-10,857.43%
|
-3,452.74%
|
-5,605.68%
|
-1,699.26%
|
-9,321.76%
|
-965.41%
|
-335.97%
|
EPS
2 |
-25.50
|
-24.75
|
-16.35
|
-13.80
|
-8.810
|
-2.515
|
-3.855
|
-6.830
|
Free Cash Flow
|
-76.72
|
-72.04
|
-52.88
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-3,449.6%
|
-13,217.43%
|
-3,014.65%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/25/21
|
3/17/22
|
3/29/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.916
|
0.592
|
0.244
|
0.152
|
0.678
|
0.106
|
0.174
|
0.035
|
0.393
|
2.769
|
0.065
|
0.065
|
0.0667
|
0.0667
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-16.06
|
-15.14
|
-15.76
|
-16.02
|
-18.33
|
-17.3
|
-16.24
|
-15.65
|
-12.62
|
-10.64
|
-19.3
|
-3.305
|
-3.3
|
-3.3
|
Operating Margin
|
-1,752.73%
|
-2,558.28%
|
-6,461.07%
|
-10,537.5%
|
-2,704.13%
|
-16,323.58%
|
-9,335.06%
|
-44,725.71%
|
-3,211.96%
|
-384.29%
|
-29,700%
|
-5,084.62%
|
-4,949.75%
|
-4,949.75%
|
Earnings before Tax (EBT)
1 |
-16.02
|
-15.09
|
-15.7
|
-15.84
|
-17.91
|
-16.7
|
-15.62
|
-15.04
|
-12.08
|
-14.53
|
-18.75
|
-2.751
|
-2.696
|
-2.696
|
Net income
1 |
-16.02
|
-15.09
|
-15.7
|
-15.84
|
-17.91
|
-16.7
|
-15.62
|
-15.05
|
-12.08
|
-14.53
|
-14.03
|
-4.476
|
-3.448
|
-2.598
|
Net margin
|
-1,748.47%
|
-2,548.82%
|
-6,433.2%
|
-10,422.37%
|
-2,641.89%
|
-15,750.94%
|
-8,978.16%
|
-42,994.29%
|
-3,073.28%
|
-524.88%
|
-21,577.69%
|
-6,885.38%
|
-5,171.74%
|
-3,896.81%
|
EPS
2 |
-4.350
|
-2.400
|
-3.300
|
-3.300
|
-3.750
|
-3.600
|
-3.450
|
-3.150
|
-2.570
|
-
|
-1.495
|
-0.4300
|
-0.3350
|
-0.2600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/17/22
|
5/12/22
|
8/11/22
|
11/10/22
|
3/29/23
|
5/11/23
|
8/10/23
|
11/9/23
|
3/19/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
120
|
100
|
137
|
77.6
|
-
|
27.4
|
67.4
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-76.7
|
-72
|
-52.9
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
1.25
|
0.4
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
56.25%
|
72.48%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/25/21
|
3/17/22
|
3/29/23
|
3/19/24
|
-
|
-
|
-
|
Last Close Price
1.87
USD Average target price
1
USD Spread / Average Target -46.52% Consensus |
1st Jan change
|
Capi.
|
---|
| -51.43% | 21.78M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|